← Home
GlaxoSmithKline 
Pharma / Pharma and biotechnology
📢 Press Releases
| Date | Press release |
|---|---|
| 2025-05-28 07:00:00 | Spero Therapeutics And Gsk Announce Pivot-po Phase 3 Study For Tebipenem Hbr Stopped Early For Efficacy Following Review By Independent Data Monitoring Committee If approved, tebipenem hbr could be the first oral carbapenem antibiotic for us patients with complicated urinary tract infections (cutis) an estimated 2.9 million cases of cutis are treated annually in the us 1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs 2 data from the pivot-po trial to be part of a planned us food and drug administration (fda) filing in 2h 2025 that spero’s development partner, gsk, intends to submit cambridge, mass., may 28, 2025 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) and gsk plc (lse/nyse: gsk), today announced that the pivotal phase 3 pivot-po trial evaluating tebipenem hbr, an investigational oral treatment for complicated urinary tract infections (cutis), including pyelonephritis, met its primary endpoint and will stop early for efficacy (nct06059846).3 the decision follows a recommendation from an independent data monitoring committee (idmc) that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial. |
| 2025-05-22 16:15:00 | Nucala (mepolizumab) Approved By Us Fda For Use In Adults With Chronic Obstructive Pulmonary Disease (copd) Philadelphia--(business wire)--gsk plc (lse/nyse: gsk) today announced that the us food and drug administration (fda) has approved nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled copd and an eosinophilic phenotype. fda’s approval was based on data from the positive matinee and metrex phase iii trials. across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualized rate of moderate/s. |
| 2025-05-14 02:14:00 | Gsk To Acquire Efimosfermin, A Phase Iii-ready Potential Best-in-class Specialty Medicine To Treat And Prevent Progression Of Steatotic Liver Disease (sld) Cambridge, mass.--(business wire)--gsk plc (lse/nyse: gsk) and boston pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which gsk will acquire boston pharmaceuticals’ lead asset, efimosfermin alfa. efimosfermin is a phase iii-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic. |
| 2025-05-09 09:00:00 | Gsk And Lifetime® Launch Original Movie To Raise Awareness About The Impact Of Meningitis Philadelphia--(business wire)-- #adolescents--gsk and lifetime® launch original movie to raise awareness about the impact of meningitis. |
| 2025-04-30 09:41:00 | Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | Gsk Leads Cervarix Market Amid Global Vaccination Efforts The cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. key drivers include rising hpv awareness, vaccination rates, and global immunization programs. gsk plc leads the market, with cervarix targeting hpv-linked conditions like cervical cancer. advanced hpv vaccines and personalized immunization strategies are emerging trends. the report details market dynamics, historical data, and future growth projections. the cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. key drivers include rising hpv awareness, vaccination rates, and global immunization programs. gsk plc leads the market, with cervarix targeting hpv-linked conditions like cervical cancer. advanced hpv vaccines and personalized immunization strategies are emerging trends. the report details market dynamics, historical data, and future growth projections. |
| 2025-04-17 08:00:00 |
|
| 2025-04-16 17:36:00 |
|
| 2025-04-16 16:57:00 |
|
| 2025-04-08 07:00:00 |
|
| 2025-04-07 16:30:00 |
|
| 2025-04-07 16:00:00 |
|
| 2025-04-07 15:45:00 |
|
| 2025-04-07 13:30:00 |
|
| 2025-04-07 12:19:00 |
|
| 2025-04-07 11:00:00 |
|
📰 Browse additional press releases for GlaxoSmithKline!
Sign up for free or log in🙌 Join now to get "The Checklist Value Investor — A Smarter Way to Pick Stocks" at no cost